BMS-986144

pan-genotype HCV NS3/4A protease inhibitor

proj. oral QD dosing, well-tolerated in rodent

deuteration reduced CYP TDI

J. Med. Chem., Nov. 23, 2020

Bristol-Myers Squibb, NJ + MA + CT + IN

Bristol-Myers Squibb (BMS) pan-genotype HCV NS3/4A protease inhibitor


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks